PUBLICATION

5-Benzylidene-2,4-thiazolidenedione derivatives: Design, synthesis and evaluation as inhibitors of angiogenesis targeting VEGR-2

Authors
Bhanushali, U., Rajendran, S., Sarma, K., Kulkarni, P., Chatti, K., Chatterjee, S., Ramaa, C.S.
ID
ZDB-PUB-160709-11
Date
2016
Source
Bioorganic chemistry   67: 139-147 (Journal)
Registered Authors
Chatti, Kiranam
Keywords
5-Benzylidene-2,4-thiazolidinediones, CAM assay, Docking, VEGFR2, Zebrafish embryo
MeSH Terms
  • Animals
  • Benzylidene Compounds/chemical synthesis
  • Benzylidene Compounds/chemistry
  • Benzylidene Compounds/pharmacology*
  • Dose-Response Relationship, Drug
  • Drug Design*
  • Humans
  • Molecular Structure
  • Neovascularization, Pathologic/drug therapy*
  • Neovascularization, Pathologic/pathology
  • Protein Kinase Inhibitors/chemical synthesis
  • Protein Kinase Inhibitors/chemistry
  • Protein Kinase Inhibitors/pharmacology*
  • Structure-Activity Relationship
  • Thiazoles/chemical synthesis
  • Thiazoles/chemistry
  • Thiazoles/pharmacology*
  • Vascular Endothelial Growth Factor Receptor-2/antagonists & inhibitors*
  • Vascular Endothelial Growth Factor Receptor-2/metabolism
  • Zebrafish
PubMed
27388635 Full text @ Bioorg. Chem.
Abstract
A series of novel 5-benzylidene-2,4-thiazolidinediones were designed as inhibitors of angiogenesis targeting VEGFR-2. In docking study, molecules showed similar way of binding with VEGFR-2 as that of the co-crystallized ligand. Compounds were then synthesized, purified and characterized by spectroscopic techniques. Compounds 3f and 3i were found to be most active in the series showing good inhibition of angiogenesis in both CAM and in zebrafish embryo assays. Compound 3i also exhibited IC50 of 0.5μM against VEGFR-2.
Genes / Markers
Figures
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping